60 Degrees Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results presented a mixed performance against consensus: revenue beat by 12.38% at $207.9K vs. $185K expected, while Normalized Net Income missed at -$2.3M vs. -$2.27M expected. Gross margin significantly underperformed consensus at 27.32% vs. 65.00% targeted, primarily due to the transition from lower-cost imported Kodatef back to standard child-resistant Arakoda packaging in the U.S. and increased yield losses. Q2 GAAP EPS of -$0.90 was below the -$0.735 mean estimate, exacerbated by higher R&D expenses as babesiosis trials reached full activity.